Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the American College of Cardiology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0735-1097(98)00557-9PMID 9935017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sulfonylurea receptors and mechanism of sulfonylurea action.

  2009cited by this paper
• The sulfonylurea controversy: more questions from the heart.

  1998cited by this paper
• Induced septal infarction/nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy.

  1998cited by this paper
• Sulfonylureas and mortality in diabetic patients after myocardial infarction.

  1998cited by this paper
• Operative condition-dependent response of cardiac ATP-sensitive K+ channels toward sulfonylureas.

  1998cited by this paper
• Sulfonylureas and Mortality in Diabetic Patients After Myocardial Infarction

  1998cited by this paper
• Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction

  1997cited by this paper
• Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.

  1997cited by this paper
• Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

  1997cited by this paper
• Beta 2-adrenergic dilation of resistance coronary vessels involves KATP channels and nitric oxide in conscious dogs.

  1997cited by this paper
• Plasminogen Activator Inhibitor—1 in Nonobese Subjects with Non-Insulin-Dependent Diabetes Mellitus

  1996cited by this paper
• Dual effect of glyburide, an antagonist of KATP channels, on metabolic inhibition-induced Ca2+ loading in cardiomyocytes.

  1996cited by this paper
• Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.

  1996cited by this paper
• Role of Sulfonylureas in Non-Insulin-Dependent Diabetes Mellitus: Part II - “The cons”

  1996cited by this paper
• Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.

  1996cited by this paper
• Thrombosis in ischemic heart disease.

  1996cited by this paper
• Appointment of New Associate Editor for Circulation

  1996cited by this paper
• A disrupter of actin microfilaments impairs sulfonylurea-inhibitory gating of cardiac KATP channels.

  1996cited by this paper
• Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.

  1996cited by this paper
• Role of Sulfonylureas in Non-Insulin-Dependent Diabetes Mellitus: Part I - “The pros”

  1996cited by this paper
• Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.

  1996cited by this paper
• Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis.

  1996cited by this paper
• Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration.

  1996cited by this paper
• Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions.

  1996cited by this paper
• Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

  1995cited by this paper
• Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Myocardial Infarction Data Acquisition System Study Group.

  1995cited by this paper
• Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs.

  1995cited by this paper
• ATP-sensitive potassium channels and myocardial preconditioning

  1995cited by this paper
• Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group.

  1995cited by this paper
• Environmental and Genetic Factors in Relation to Elevated Circulating Levels of Plasminogen Activator Inhibitor-1 in Caucasian Patients with Non-Insulin-Dependent Diabetes Mellitus

  1995cited by this paper
• Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.

  1995cited by this paper
• Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: A statewide study

  1995cited by this paper
• Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients

  1994cited by this paper
• Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

  1994cited by this paper
• Protective Effects of ATP‐Sensitive Potassium‐Channel Openers in Experimental Myocardial Ischemia

  1994cited by this paper
• Ischemic Preconditioning During Coronary Angioplast Is Prevented by Glibenclamide, a Selective ATP‐Sensitive K+ Channel Blocker

  1994cited by this paper
• Glibenclamide prevents coronary vasodilation induced by beta 1-adrenoceptor stimulation in dogs.

  1994cited by this paper
• Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?

  1993cited by this paper
• Late outcome after percutaneous transluminal coronary angioplasty during acute myocardial infarction.

  1993cited by this paper
• The pharmacology of ATP-sensitive potassium channels.

  1993cited by this paper
• Arteriolar tone is determined by activity of ATP-sensitive potassium channels.

  1993cited by this paper
• Sulfonylureas in NIDDM

  1992cited by this paper
• Inhibition of ATP-sensitive K+ channels in cardiac muscle by the sulphonylurea drug glibenclamide.

  1992cited by this paper
• The sulfonylurea receptor.

  1992cited by this paper
• Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

  1992cited by this paper
• Glibenclamide specifically blocks ATP-sensitive K+ channel current in atrial myocytes of guinea pig heart.

  1990cited by this paper
• Oral hypoglycemic agents.

  1989cited by this paper
• Antidiabetic sulfonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels.

  1988cited by this paper
• Myocardial infarction in patients with diabetes mellitus.

  1988cited by this paper
• Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.

  1986cited by this paper
• Prevalence and Mortality of Acute Myocardial Infarction in Patients with Diabetes

  1985cited by this paper
• A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

  1970cited by this paper

• High Accuracy Detection of S and T Peaks in ECG Signals

  2024cites this paper
• Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes

  2024cites this paper
• Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study

  2023cites this paper
• KATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

  2023cites this paper
• Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies

  2022cites this paper
• Low glucose metabolizing capacity and not insulin resistance is primary etiology of Type 2 Diabetes Mellitus: A hypothesis

  2022cites this paper
• Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives.

  2022cites this paper
• The Pharmacology of ATP-Sensitive K+ Channels (KATP).

  2021cites this paper
• Effects of COVID-19 and diabetes mellitus on apolipoprotein A1 level in the blood plasma of patients

  2021cites this paper
• COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy

  2021cites this paper
• A Review on Drug Related Problems in Type 2 DM with Combination of Sulfonylureas and Biguanides

  2021cites this paper
• Effects of Naringin on Cardiomyocytes From a Rodent Model of Type 2 Diabetes

  2021cites this paper
• Diabetic Control Agents and Their Impact on Cardiac Surgery Patients: A Clinical Overview

  2020influential citation
• RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020

  2020cites this paper
• Effects of antidiabetic medications on cardiovascular outcomes

  2020cites this paper
• Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus—Part 1

  2020influential citation
• Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients

  2020cites this paper
• RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020

  2020cites this paper
• Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

  2019cites this paper
• Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications

  2019cites this paper
• Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease

  2018cites this paper
• Minireview of Adverse Effects of Some Drugs Used in Diabetes Mellitus

  2018cites this paper
• Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force”

  2018cites this paper
• ATP-Sensitive Potassium Channels and Their Physiological and Pathophysiological Roles.

  2018cites this paper
• Glibenclamide Prevents Hypoglycemia-Induced Fatal Cardiac Arrhythmias in Rats

  2018cites this paper
• Individualisation du traitement de l’hyperglycémie du diabète de type 2 : choix selon la classe thérapeutique, ou selon la molécule

  2017cites this paper
• Oral Antihyperglycemic Therapy for Type 2 Diabetes

  2017cites this paper
• The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective

  2017cites this paper
• Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction

  2017cites this paper
• Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

  2017cites this paper
• Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

  2017cites this paper
• Cardiovascular safety of oral antidiabetic therapy in type 2 diabetes mellitus- review article

  2017influential citation
• Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.

  2017cites this paper
• Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

  2017cites this paper
• Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome

  2017cites this paper
• Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines

  2016cites this paper
• Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications

  2016cites this paper
• Acute Coronary Syndrome, Myocardial Infarction, Heart Failure, and Stable Coronary Artery Disease—Specific Considerations in Diabetes

  2016cites this paper
• Cardiovascular effects of anti-diabetes drugs

  2016cites this paper
• Hypertension and Diabetes: Need for Combination Therapy

  2016cites this paper
• Cardiovascular safety of anti-diabetic drugs.

  2016cites this paper
• Diabetes and Exercise

  2016cites this paper
• Transcriptional analysis caveolae-related transcripts in the ischaemic- intolerant ageing mouse heart

  2016cites this paper
• Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy

  2016cites this paper
• Drug Treatment of Stable Coronary Artery Disease

  2016cites this paper
• The Influence of Diabetes Mellitus in Myocardial Ischemic Preconditioning

  2016cites this paper
• Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study

  2016cites this paper
• Oral Hypoglycemic Agents: Sulfonylureas and Meglitinides

  2016cites this paper
• Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.

  2016cites this paper
• Sulfonylureas and their use in clinical practice

  2015cites this paper
• Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

  2015cites this paper
• Cardiac NO signalling in the metabolic syndrome

  2015cites this paper
• Clinical features and treatment of coronary heart disease in diabetes

  2015cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?

  2015cites this paper
• Combination therapy in type 2 diabetes mellitus

  2015cites this paper
• Cardiovascular benefits and risk profiles of oral anti-diabetic agents: current evidence and ongoing trials

  2015influential citation
• Sulfonylureas and meglitinides: insights into physiology and translational clinical utility

  2015cites this paper
• Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011.

  2015cites this paper
• Mortality risk among sulfonylureas: a systematic review and network meta-analysis.

  2015cites this paper
• Hormones Part 2: Insulin and Other Glucose-Controlling Medications

  2015cites this paper
• Expressão do precondicionamento isquêmico em pacientes com diabetes mellitus tipo 2 e doença arterial coronariana

  2015cites this paper
• Treating the elderly diabetic patient: special considerations

  2014cites this paper
• Vascular Complications of Diabetes Mellitus

  2014cites this paper
• Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2

  2014cites this paper
• Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study

  2014cites this paper
• Impact of hypoglycemic agents on myocardial ischemic preconditioning.

  2014cites this paper
• Cardiovascular safety profile of currently available diabetic drugs.

  2014cites this paper
• Alternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic Inflammation.

  2014cites this paper
• Adipositas und deren Bedeutung für ausgewählte neurologische Erkrankungen

  2014cites this paper
• Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus

  2014cites this paper
• Association between first‐line monotherapy with sulphonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study

  2014cites this paper
• Combination therapy with metformin plus sulphonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality

  2014cites this paper
• Metabolic Syndrome and Obesity : Targets and Therapy Dovepress

  2014cites this paper
• Delirium Screening in Cardiac Surgery (DESCARD): a useful tool for nonpsychiatrists.

  2014cites this paper
• Tuning the electrical properties of the heart by differential trafficking of KATP ion channel complexes

  2014cites this paper
• Myocardial protection by remote ischaemic pre‐conditioning is abolished in sulphonylurea‐treated diabetics undergoing coronary revascularisation

  2014cites this paper
• Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis

  2013cites this paper
• Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus

  2013cites this paper
• Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

  2013cites this paper
• Roles of p38-MAPK in insulin resistant heart: evidence from bench to future bedside application.

  2013cites this paper
• Sulfonylureas and meglitinides: historical and contemporary issues.

  2013cites this paper
• Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?

  2013cites this paper
• Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Role of Kir6.2 subunits of ATP-sensitive potassium channels in endotoxemia-induced cardiac dysfunction

  2013cites this paper
• Recent HbA1c Values and Mortality Risk in Type 2 Diabetes. Population-Based Case-Control Study

  2013cites this paper
• Current medical treatment of diabetes type 2 and long term morbidity: how to balance efficacy and safety?

  2013cites this paper
• Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach.

  2013cites this paper
• Divergent effects of various diabetes drugs on cardiovascular prognosis.

  2013cites this paper
• Polarograpy of Zn (II)-Tolbutamide complex and its Pharmacological Study

  2013cites this paper
• ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Glibenclamide: proven facts, perspectives, discussions

  2013cites this paper
• Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность

  2012cites this paper
• Effect of Pioglitazone on Arterial Baroreflex Sensitivity and Sympathetic Nerve Activity in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

  2012influential citation
• Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome.

  2012cites this paper
• Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

  2012cites this paper
• Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data

  2012cites this paper
• Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome.

  2012cites this paper
• Diabetes management by primary health care nurses in Auckland: A cross-sectional study

  2012cites this paper
• Hyperglycemia and perioperative glucose management.

  2012cites this paper
• The impact of current and novel anti-diabetic therapies on cardiovascular risk.

  2012cites this paper